Table 2.
ART adherence and viral suppression, by study arm (N=90)
| All participans (N=90) | DSD-1VL (N=31) | DSD-2VL (N=31) | TAU (N=28) | p | |
|---|---|---|---|---|---|
| Days (SD) | Days (SD) | Days (SD) | Days (SD) | ||
| ART adherence | |||||
| Self-reported number of days of ART missed in prior 30 days, at 6-month visit | 1.1 (3.5) | 0.9 (2.0) | 1.6 (5.5) | 0.6 (1.1) | 0.55 |
| Self-reported number of days of ART missed in prior 30 days, at 12-month visit | 0.9 (3.4) | 0.8 (1.2) | 1.1 (5.4) | 0.6 (1.1) | 0.85 |
| n (%) | n (%) | n (%) | n (%) | ||
| Viral suppression | |||||
| Virally suppressed, 3-month viral load^ | 23 (74.0) | - | 23 (74.0) | - | - |
| Virally suppressed, 5-month viral load | 62 (68.9) | 22 (71.0) | 21 (67.7) | 19 (67.9) | 0.80 |
| Eligible to enter DSD schedule& | 37 (59.7) | 19 (61.3) | 18 (58.1) | - | 0.796 |
| Virally suppressed, 12-month viral load | 69 (76.7) | 25 (80.7) | 25 (80.7) | 19 (67.9) | 0.41 |
| Virally suppressed, 12-month viral load, among those completing study* | 69 (82.1) | 25 (83.3) | 25 (80.7) | 19 (82.6) | 1.00 |
ART: antiretroviral therapy; DSD: differentiated service delivery
^only includes participants in DSD-2VL
& only includes participants in DSD-1VL and DSD-2VL; does not include 3 participants in DSD-1VL and 1 participant in DSD-2VL who were ineligible for DSD appointment schedule because of pregnancy or tuberculosis; p-value for chi-square test comparing DSD-1VL and DSD-2VL
*denominators are N=30 (DSD-1VL), N=31 (DSD-2VL), N=24 (TAU)